Lenvaxen 4 mg (Lenvatinib) Capsules

Lenvaxen 4 contains lenvatinib, an oral targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class. It is used as part of specific treatment regimens for certain advanced or unresectable cancers.

Lenvatinib works by inhibiting several receptor tyrosine kinases involved in tumor growth and the formation of new blood vessels that can supply a tumor. By interfering with these signaling pathways, it can help slow cancer-cell proliferation and reduce tumor-supporting angiogenesis.

Depending on the approved indication and treatment combination, lenvatinib may be used for:

• Differentiated thyroid cancer that is progressive, recurrent, or not adequately responsive to radioactive iodine treatment.
• Advanced renal cell carcinoma in combination with another anticancer medicine as prescribed by an oncologist.
• Unresectable hepatocellular carcinoma in appropriately selected patients.
• Certain other advanced cancers may be treated with lenvatinib in combination regimens according to local regulatory approvals and specialist guidance.

The therapeutic effect depends on the cancer type, disease stage, treatment combination, and individual patient factors. Lenvatinib is a prescription medicine and should be used only under the supervision of an appropriately qualified healthcare professional.

Active Ingredient:
Lenvatinib 4 mg

Dosage Form:
Oral hard capsule

Pharmacological Class:
Tyrosine Kinase Inhibitor (TKI)

Therapeutic Class:
Antineoplastic / Targeted Anticancer Agent

The capsule contains 4 mg of lenvatinib as the active pharmaceutical ingredient. Other inactive ingredients may be present to provide the capsule's required structure, stability, and manufacturing characteristics. Patients with known allergies or sensitivities to any component should consult their healthcare professional before use.

The appropriate lenvatinib dose depends on the type of cancer, treatment regimen, combination medicines, liver and kidney function, and individual tolerability. Therefore, the prescribed dose should always be followed rather than selecting a dose independently.

General Administration

• Take Lenvaxen 4 exactly as prescribed by the treating oncologist.
• Lenvatinib is generally administered once daily, with or without food, depending on the prescribed regimen.
• Swallow the capsule whole with water.
• Do not crush, chew, or open the capsule unless a healthcare professional has specifically provided an appropriate alternative administration method.
• Try to take the medicine at approximately the same time each day.
• Treatment may require dose interruption, reduction, or discontinuation if significant adverse effects occur.
• Regular medical monitoring may be required during therapy, including blood pressure, kidney and liver function, thyroid function, and other laboratory parameters.

Missed Dose

If a dose is missed, follow the instructions provided by the prescribing healthcare professional or the product's approved prescribing information. Do not take an extra dose to compensate for a missed dose. The appropriate interval before taking the next dose can depend on the specific treatment regimen.

Important Usage Instructions

Lenvatinib should be taken only for the cancer indication and regimen prescribed by a specialist. Do not change the dose, stop treatment, or restart treatment without medical advice. Because lenvatinib can cause clinically important adverse reactions and drug interactions, ongoing follow-up with the treating healthcare team is essential.